Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 2/20 | 0.40 |
| ▸ | PDE8B | O95263 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14398395 | 1.00 | HPGD (0.47) | HPGDEPHX1HSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL31336384 | 1.00 | HPGD (0.47) | HPGDEPHX1HSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL1991177 | 0.98 | HSD17B10 (0.45) | HPGDEPHX1HSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL2896341 | 0.98 | HSD17B10 (0.45) | HPGDEPHX1HSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL1991179 | 0.98 | HSD17B10 (0.45) | HPGDEPHX1HSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL40804 | 0.94 | HSD17B10 (0.49) | HPGDHSD17B10SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL338312 | 0.94 | HSD17B10 (0.49) | HPGDHSD17B10SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL190173 | 0.94 | HSD17B10 (0.49) | HPGDHSD17B10SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL17980096 | 0.87 | HSD17B10 (0.41) | HPGDEPHX1HSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL2030521 | 0.87 | HSD17B10 (0.41) | HPGDEPHX1HSD17B10SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695260-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20240383922-A1 | KRAS Modulating Compounds | GILEAD SCIENCES, INC. | 2024-11-21 | — | — | US | disclosed |
| WO-2024215754-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| US-11718638-B2 | Compounds, compositions and methods for synthesis | WAVE LIFE SCIENCES LTD. (SG) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718638-B2 | Compounds, compositions and methods for synthesis | ALKBH1, DUT, RNGTT | HPGD 3802/4885EPHX1 2749/4885HSD17B10 4428/4885 |
| US-20240383922-A1 | KRAS Modulating Compounds | KRAS, NRAS, HRAS | HPGD 2436/4885EPHX1 3345/4885HSD17B10 4557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.